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Abstract  
Peroxisome proliferator activated receptor beta/delta (PPARβ/δ) is a nuclear receptor ubiquitously 
expressed in cells whose signaling controls inflammation and metabolism. However, there are 
great discrepancies in understanding the role of PPARβ/δ, having both anti- and pro-effects on 
inflammation. Understanding the PPARβ/δ mechanism of action may provide new molecular 
mechanisms for treating a variety of inflammatory-related diseases.  
We studied the PPARβ/δ-regulation of LPS-induced inflammation of pulmonary artery, bronchi 
and parenchyma from rat, using different combinations of agonists (GW0742 or L-165402) and 
antagonists (GSK3787 or GSK0660). LPS-induced inflammation is largely regulated by PPARβ/δ 
in the pulmonary artery, but it is a minor factor in bronchi or parenchyma. Agonists do not 
significantly inhibit inflammation, but activates the PPARβ/δ induction mode of action. 
Surprisingly, co-incubation of the tissue with agonist plus antagonist shows anti-inflammatory 
effects and switches the PPARβ/δ mode of action from induction to trans-repression, indicating 
that the PPARβ/δ induction mode of action is pro-inflammatory and the trans-repression anti-
inflammatory. Us of Computational chemistry methods indicates that PPARβ/δ agonists are 
predicted to form polar interactions with the residues His287, His413 and Tyr437 whilst PPARβ/δ 
antagonists form polar interactions with the residues Thr252 and Asn307. Further, our modelling 
indicates favorable binding energies and the feasibility of simultaneous binding of two ligands in 
the PPARβ/δ binding pocket. In summary, this study provides novel insight into the complex 
relationship between ligand binding profiles and functional outcomes in a rat lung inflammation 
model, which will help inform the design of novel therapies for inflammatory lung diseases. 
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Introduction 
PPARβ/δ are ligand dependent transcription factors that belong to the nuclear receptor family 
(1). They are ubiquitously expressed in all cells tested (2) and control key biological functions 
such as lipid metabolism, glucose metabolism, immune response, inflammation, cell 
proliferation, cell migration, apoptosis and carcinogenesis (3-5). Consequently, PPARβ/δ is 
emerging as a therapeutic target for the treatment of disorders associated with metabolic 
syndrome, although there are no marketed drugs specifically targeting PPARβ/δ yet. 
Research reported mainly on animal models such as mice, rats or rhesus monkeys indicates 
that PPARβ/δ agonists result in a number of favorable pharmacological effects including 
reduced weight gain, increased metabolism in the skeletal muscle and cardiovascular function, 
suppression of atherogenic inflammation and improvement of the blood lipid profile, which are 
common abnormalities in patients with metabolic syndrome (3,6,7). 
These encouraging results led to the first clinical trials on humans. Glaxo Smith Kline (GSK) 
developed the agonist GW501516 (Endurobol), a promising compound that completed proof-of-
concept clinical trials successfully for dyslipidemia (8) and hypocholesteremia (9). However, 
further studies showed a suspected link with tumor development (10,11), and any further clinical 
trial with GW501516 was suspended. 
Nevertheless, the interest in PPARβ/δ continues and in the last few years several compounds 
targeting PPARβ/δ were developed, although just a few of these molecules reached clinical 
trials. One of them was MBX-8025, which reached Phase II clinical trial for patients with non-
alcoholic steatohepatitis and primary sclerosing cholangitis; unfortunately, this study was 
terminated early when patients developed early signs of liver damage as indicated by liver 
biopsy (12). 
PPARβ/δ can be activated by numerous endogenous ligands such as eicosanoids, fatty acid, 
metabolites derived from arachidonic acid and linoleic acid (13-15) as well as exogenous 
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synthetic ligands like GW0742, L-165041, MBX-8025 and GW501516, and can also be 
repressed by the two synthetic antagonists GSK3787 and GSK0660. 
After ligand activation, PPARβ/δ regulates genes by two different mechanisms, induction and 
trans-repression. In the induction mode, PPARβ/δ forms a complex with the retinoid X receptor 
(RXR) and together, as a heterodimer, binds the promoter of the target genes (PPRE). In the 
absence of ligand, co-repressor proteins and histone deacetylases (HDACs) are bound to the 
heterodimer which tight the chromatin and prevent it from binding to the PPRE sites (16). The 
presence of ligand induces a conformational change of PPARβ/δ which promotes the binding of 
co-activators, releases the co-repressor proteins, induces histone acetylation and methylation 
and finally allows the transcription of the target genes (17,18). 
In the trans-repression mode PPARβ/δ regulates gene expression in a PPRE-independent 
manner through the regulation (mostly suppression) of other transcription factors, including 
nuclear factor-κB (NF-κB) (19), activator protein (AP-1) (20) and B cell lymphoma 6 (Bcl6) (21). 
However, there are great discrepancies in the literature about the effect of the ligand-activation 
of PPARβ/δ in the cell, and both pro- and anti- effects in inflammation (22,23), cell proliferation 
(24,25) and migration (26,27) have been reported. PPARβ/δ receptor appears to be a sensitive 
molecular switch that has both endogenous and exogenous ligands which control cellular 
function through changes in very small concentration range. Added to this, in any cell or tissue, 
the activity of PPARβ/δ may also depend on its promoter activity and relative expression, as well 
as presence and activity of co-repressor and co-activator proteins. It has been shown that 
GW0742 is capable of behaving as an agonist activating the transcription pathway at lower 
concentrations (nM) and antagonist inhibiting this effect at higher concentrations (μM) (28). In 
the same line, a study in a model of systemic inflammation in mice showed that higher doses of 
GW0742 (0.3 mg/kg) triggered a pro-inflammatory response, whereas a lower concentration 
(0.03 mg/kg) showed an anti-inflammatory trend, although without a significant difference (29). 
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Understanding how PPARβ/δ switches between induction and trans-repression mode of action 
and how this determines cellular function is of great interest and may provide new molecular 
targets for treating a variety of inflammation-dependent diseases, including atherosclerosis, 
diabetes, and cancer. Whether differences in endogenous and exogenous ligands induce 
slightly different genes in different cells is a great possibility, and one that has not been so far 
explored. The question that needs to be addressed is not whether activation leads to proliferation 
and cancer, but whether the type of agonist activation and the subsequent molecular control can 
be adjusted to place the cell into a non-proliferative and non-inflammatory state of gene 
expression. A parallel argument has been made on the cause of the side effects of 
glucocorticoids; the type of ligand determines whether the glucocorticoid receptor forms a 
homodimer, and the subsequent type of trans-repression and transcriptional control exerted 
leads to change in cellular function (30). Therefore, we hypothesized that PPARβ/δ acts as a 
molecular switch between induction and trans-repression and depending on which mechanism 
is triggered, it will have pro- or anti-effects.  
In order to address these fundamental questions, we investigated the varying effects of 
PPARβ/δ ligands on inflammation in three isolated tissues within the lung: pulmonary artery, 
bronchi and parenchyma. Using marker genes to indicate the level of induction and trans-
repression we showed how different tissues respond, and using computational docking of the 
PPARβ/δ with various combinations of the ligands, have insight that might explain the varying 
effects on the resulting changes in gene transcription that leads to the range of cellular functional 
changes. 
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Results 
PPARβ/δ regulation of LPS-induced lung tissue inflammation 
Three main tissues were identified in the lung; pulmonary artery, bronchi and parenchyma, and 
the expression of PAPRβ/δ was verified in all three tissues (Supplementary Figure 1). NO 
production from pulmonary artery, bronchi and lung parenchyma was measured after 8 h, 20 h 
and 24 h of incubation (Figure 1), and indicates that the effects of the treatments for all the 
tissues tested are greatest at 24 h of incubation.  
The pulmonary artery rings used for the time-line incubations were too small to use for further 
experiments, therefore the same experiment was repeated using bigger rings and NO and IL-6 
production was measured after 24 h incubation (Figure 2). LPS significantly increased NO by 4 
to 10-fold (Figure 2A, 2B), as expected. In the presence of PPARβ/δ ligands GW0742 and 
GSK3787 (Figure 2A) or L-165041 and GSK0660 (Figure 2B), nitrite production is not 
significantly different than LPS alone. In contrast, the combination of agonist GW0742 and 
antagonist GSK3787, or L-165041 and GSK0660 (Figure 2A, 2B) significantly reduces NO 
production. This indicates that the co-incubation with the agonist-antagonist attenuates the LPS-
induced NO production more effectively. To confirm the inflammation IL-6 was measured by 
ELISA (Figure 2C, 2D). Again, LPS increases IL-6 production by 10-fold, and the PPARβ/δ 
ligands GW0742, L-165041 and GSK0660 do not have a significant effect on their own. 
However, the antagonist GSK3787 significantly decreases IL-6 production by half, as well as 
the co-incubation with GW0742-GSK3787 or L-165041-GSK0660. 
The same experiment was performed in bronchi with similar profile to pulmonary artery 
(Supplementary Figure 2); LPS increases the production of NO from 2- to 4-fold with LPS, 
which is decreased in the presence of the co-incubation with PPARβ/δ agonist and antagonist, 
although this reduction showed not to be statistically significant. LPS also increases IL-6 
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production 2 to 4-fold, but this increment is not significantly affected by the PPARβ/δ ligands 
used.  
In parenchyma, LPS increases NO and IL-6 production by 2-fold and 3-4-fold respectively 
(Supplementary Figure 3). The PPARβ/δ ligands do not have any significant effect on LPS-
induced NO, although the same pattern of NO reduction when agonist and antagonist are 
present at the same time is followed. Similarly, the PPARβ/δ ligands on their own do not have 
an effect on LPS-induced IL-6 production, however, the co-incubation with GW0742 and 
GSK3787 significantly reduces IL-6 by 1-fold. 
PPARβ/δ molecular switch in pulmonary artery 
To understand the PPARβ/δ molecular switch, marker genes for the induction and trans-
repression mode of action were chosen, and the transcription/repression of these marker genes 
were linked to the pro- and anti-inflammatory responses of the tissues tested. With that aim, 
Pdk-4 and Angptl-4 were chosen as markers of the induction mode of action and Timp-1, 
Serpine-1 and Id2 were chosen as markers for the trans-repression mode of action. The 
performance of the primers used were tested in the tissues and the data is summarized in 
Supplementary Table 1. 
In pulmonary artery, GW0742 significantly increases the transcription of Pdk-4 by 7-fold (Figure 
3A) and Angptl-4 by 3-fold (Figure 3B), which is inhibited by the antagonist GSK3787. The 
transcription of Timp-1 (Figure 3C) and Serpine-1 (Figure 3D) is increased by LPS in the 
pulmonary artery, and the agonist-activation of PPARβ/δ blocks the transcription by 3-fold 
compared to LPS. Interestingly, the treatment with LPS+GSK3787 increases the transcription 
of Timp-1 which is again repressed by the treatment with LPS+GW0742+GSK3787. LPS does 
not induce the expression of Id2 in the pulmonary artery, and similarly its expression is not 
affected by the PPARβ/δ ligands (Figure 3E). 
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The expression of Nos2, the gene that encodes for iNOS, is significantly increased by LPS, and 
its expression is inhibited by GW0742 (Figure 3F), although this inhibition is not significant. 
Interestingly the treatment with LPS+GW0742+GSK3787 does not affect the expression of 
Nos2. Similar to pulmonary artery samples, GW0742 increased the expression of Pdk-4 by 2-
fold, although this increment is not significant, and the presence of GSK3787 inhibited its 
expression (Supplementary Figure 4A). 
Angptl-4 did not amplify in bronchi samples and the expression of Timp-1, Serpine-1 and Id2 
showed not to be regulated by the treatments (Supplementary Figure 4). The transcription of 
Nos2 is significantly increased by LPS and to more extent by GW0742. The presence of 
GSK3787 significantly reduces the transcription of Nos2 compared to LPS+GW0742, although 
it is still significantly higher than control (Supplementary figure 4E). 
GW0742 increases the transcription of Angptl-4 by 3-fold in lung parenchyma, however the rest 
of the marker genes tested were not affected by the PPARβ/δ ligands (Supplementary Figure 
5). 
Computational Chemistry: PPARβ/δ Docking analysis 
Docking of one PPARβ/δ ligand 
The PPARβ/δ-LBD crystal structure 3TKM has an X-ray resolution of 1.95 Å and was co-
crystallized with GW0742, the same agonist that was used during the development of this 
project, therefore this structure was chosen for our docking experiments. 
The two PPARβ/δ agonists used in the previous experiments GW0742 and L-165041 as well as 
the two antagonists GSK3787 and GSK0660 were docked into the crystal structure of the LBD 
of PPARβ/δ. The best eight hits were analyzed by Pymol to identify the residues that form polar 
interactions with each of the different poses of the ligands (Table 2). 
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Docking of GW0742 
The most stable orientation of GW0742 within the PPARβ/δ binding pocket predicted by 
Autodock Vina (green) was compared to the real GW0742 present in the crystal structure (pink) 
(Figure 4A). Figure 4B  is a more detailed image showing the residues that form polar 
interactions with GW0742 (His247, His413 and Tyr437) according to Pymol, whereas  Figure 
4C is a 2D image created by Ligplot+ showing how the head of GW0742 forms the polar bindings 
and the tail is surrounded by the hydrophobic amino acids. 
Docking of GSK3787 
GSK3787 binds in a slightly different place than GW0742, although there is some overlapping 
of the binding sites (Figure 5A). Also, the amino acids involved in the polar interaction of 
GSK3787 predicted by Pymol, Thr252 and Asn307, are different to those of the agonists (Figure 
5B) as well as the residues that interact with the hydrophobic tail of GSK3787 (Figure 5C). 
Docking of L-165042 
The most stable L-165041 orientation predicted by Autodock Vina binds in the same physical 
place as GW0742 (Supplementary Figure 6A) and the same three amino acids (His287, 
His413, Tyr437) form polar interactions with the head of L-165041 (Supplementary Figure 6B). 
The tail of L-165041 also forms hydrophobic interactions with a number of residues in common 
with GW0742, such as Val245, Arg248, Cys249, Thr253, Phe291, Leu294, Val305, Val312, 
Met417, Leu433 (Supplementary Figure 6C). 
Docking of GSK0660 
GSK0660 binds very close but not in the same binding site as GW0742 (Supplementary Figure 
7A). The amino acids involved in the polar bindings with GSK0660, Thr252, Asn307, Arg248 
and Ala306, are again different to those for the agonists, although two of them are common with 
GSK3787 (Supplementary Figure 7B). Ligplot+ predicts slightly different polar binding profile 
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(Supplementary Figure 7C), probably because these two software’s use different algorithms 
for binding prediction, although still show hydrophobic interactions common with GSK3787, such 
as Trp228, Val305 and Ala306. 
Docking of two PPARβ/δ ligands simultaneously 
In order to investigate the docking of two ligands simultaneously, the first ligand was bound in 
the most stable orientation first.  The best hit from previous docking was assigned Ligand 1, and 
then a second molecule was docked, assigned Ligand 2. The aim was to mimic the conditions 
of the experiments performed in this study and predict what could have happened at the 
molecular level. When the tissues were treated with only one ligand there is only one option for 
two ligands to bind, but when two different ligands are present at the same time either of them 
can bind first into the binding pocket. All these ligand-binding possibilities were considered and 
summarized in Table 3. A further analysis on Pymol was done for each option. 
Analysis of GW0742 and GSK3787 docked into GW0742-bound PPARβ/δ 
Once GW0742 is bound in the most stable orientation within the PPARβ/δ-LBD, GW0742 and 
GSK3787 can still bind at favorable energies  (-8.5 kcal/mol and  -7.7 kcal/mol respectively), 
although at very different binding sites to the most stable one and forming polar interactions with 
different residues, as shown in Figure 6.  
 
Analysis of GW0742 and GSK3787 docked into GSK3787-bound PPARβ/δ 
GW0742 and GSK3787 can also bind into the binding pocket after GSK3787 at favorable 
energies (-8.1 kcal/mol and -7.4 kcal/mol respectively). The binding site is also different to the 
most stable ones (Figure 7), but interestingly the binding site is also different to the previous 
one, when GW0742 is bound first into the binding pocket instead of GSK3787. 
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Analysis of L-165041 and GSK0660 docked into L-165041-bound PPARβ/δ 
When L-165041 is bound to the ligand binding pocket first, a second molecule of L-165041 or 
GSK0660 can bind with favorable energies (-8.3 kcal/mol and -6.5 kcal/mol respectably) and 
again, forming polar interactions with different residues. The most interesting finding is that 
GSK0660, although still in the PPARβ/δ-LBD, binds outside the binding pocket (Supplementary 
Figure 8). 
Analysis of L-165041 and GSK0660 docked into GSK0660-bound PPARβ/δ 
L-165041 and GSK0660 can also bind within the binding pocket at favorable energies (-8.1 
kcal/mol and -8.9 kcal/mol respectively) after GSK0660 is bound in the most stable orientation 
(Supplementary Figure 9), but again the binding site is different to previously when L-165041 
was bound first. 
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Discussion 
This is the first report that provides insight into the PPARβ/δ molecular switch between induction 
and trans-repression and effects on inflammation.  
PPARβ/δ is expressed in the three main tissues identified in the lung; pulmonary artery, bronchi 
and parenchyma, although at different concentrations. The expression of PPARβ/δ in pulmonary 
artery agrees with previous results where PPARβ/δ was shown to be expressed in endothelial 
cells (31). Bronchi express the lowest concentration of PPARβ/δ, which also agrees with the 
weak PPARβ/δ immunostaining of bronchial epithelial cells of mice (32), and parenchyma shows 
the highest expression of PPARβ/δ, which differs to the expression profile in mice, where the 
expression of PPARβ/δ is also weak in alveolar type II cells (32). 
The effects of PPARβ/δ ligands on LPS-induced inflammation of the tissues was studied by 
incubating the tissues with different agonists (GW0742 and L-165041) and antagonists 
(GSK3787 and GSK0660), which showed similar regulatory profile in all tissues. In general 
terms, LPS induces the release of NO and IL-6, and the incubation with one ligand (either 
agonist or antagonist) does not reduce the production of these inflammation markers. However, 
co-incubation with both an agonist and an antagonist significantly reduces LPS-induced 
inflammation.  
However, it cannot be ignored the fact that these results disagree with a large number of studies 
where the treatment with GW0742 attenuated the lung inflammation in murine models, the 
effects of GW0742 were abolished or significantly reduced by GSK0660, and the PPARβ/δ 
deletion exacerbates the lung inflammation (33-35). The difference is that these studies are in 
vivo and, although the inflammation is monitored in the lung, the whole organism is responding 
to the infection, the immune system is being activated and immune cells such as neutrophils 
and macrophages are infiltrated into the alveolar cavity. This means that there is a synergic 
response composed of different tissues and cells that makes the anti-inflammatory response 
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more effective. In the model used here, the tissues were separated from each other and the 
LPS-induced regulation of inflammation by PPARβ/δ was analyzed in isolated tissues to 
investigate our molecular switch hypothesis. Under these conditions, PPARβ/δ seems to play a 
more important role in the regulation of inflammation in the pulmonary artery than in bronchi and 
lung parenchyma. 
The initial hypothesis was that PPARβ/δ acts as a molecular switch between induction and trans-
repression and depending on which mechanism is triggered it will have pro- or anti-inflammatory 
effects. If the hypothesis is true, the results would indicate that the incubation with an agonist 
led to a pro-inflammatory state of PPARβ/δ and the incubation with the agonist and antagonist 
together switches PPARβ/δ to an anti-inflammatory state. However, the data do not provide 
enough information to conclude whether the pro- and anti-inflammatory response is regulated 
through the induction or trans-repression mode of action. With this aim, qRT-PCR was 
performed for the expression of marker genes for each mechanism of action in all treatments 
and all tissues. 
Marker genes were selected to represent the induction and trans-repression modes of action. 
Khozoie (36) and Adhikary (37) performed a genomewide analysis of genes regulated by 
PPARβ/δ in mouse keratinocytes and human myofibroblasts respectively. Khozoie (36) cross-
linked the two lists of genes regulated by PPARβ/δ and created a new list of 103 genes regulated 
by PPARβ/δ in both human and mouse models. There is a high possibility that these genes are 
regulated by PPARβ/δ in rats as well, therefore this list was used to select the induction and 
trans-repression marker genes.  
It is very tempting to accept that those genes found with PPARβ/δ bound to its promoter are 
regulated through the induction mode of action and those without PPARβ/δ bound to the 
promoter are regulated through the trans-repression mode of action, however our results 
indicate that this is incorrect. For example, Angptl-4 is well known to be regulated by induction 
mode (38-40), which agrees with Khozoie (36) results, where they found PPARβ/δ bound to the 
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promoter of Angptl-4. However, Pdk-4 is another well-known gene regulated in the induction 
mode (39-41), but Khozoie (36) did not identify PPARβ/δ bound to the promoter of the gene. 
Consequently, it can be presumed that the genes with PPARβ/δ bound to the promoter are 
regulated through the induction mode of action, but it cannot be ruled out that genes without 
PPARβ/δ in their promoter are regulated in the trans-repression mode. Therefore, other ways of 
identifying potential markers for the trans-repression mode of action are needed.  
A separate study was used to identify the genes regulated by NF-κB after LPS activation of 
human cells (42) and crosslinked with the list of 103 genes regulated by PPARβ/δ in mouse and 
human. After LPS-activation, NF-κB was found in the promoter of four genes common in the two 
lists, whose transcription was also increased (42). Two of them were selected as potential 
markers for the trans-repression mode of action of PPARβ/δ: Timp-1 and Serpine-1. The idea 
is that when PPARβ/δ is activated and functioning in the trans-repression mode of action it will 
sequester NF-κB and inhibit the transcription of the selected genes. 
Bcl-6 has shown to be another important trans-repression mechanism of action of PPARβ/δ, for 
that reason another marker gene for this pathway was identified. One study showed that LPS 
increases the transcription of Id2 in some tissues, like the brain (43), and another study showed 
that Id2 is regulated by Bcl-6 (44), therefore Id2 was chosen as a marker gene of the PPARβ/δ 
trans-repression mode of action through Bcl-6. When PPARβ/δ is not activated it sequesters 
Bcl-6, which will allow the transcription of Id2 in the presence of LPS; should PPARβ/δ become 
activated it will release Bcl-6 which will then repress the expression of Id2. Our study indicates 
that Bcl-6 response was not prominent in the LPS response in any lung tissue studied. 
The qRT-PCR of pulmonary artery showed that the activation of PPARβ/δ with GW0742 
increases the transcription of Pdk-4 and Angptl-4 and represses the transcription of Timp-1 and 
Serpine-1, indicating that agonist activation of PPARβ/δ triggers both, induction and trans-
repression. However, the presence of GW0742 and GSK3787 together does not induce the 
transcription of Pdk-4 or Angptl-4 but it still represses the transcription of Timp-1 and Serpine-1, 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted June 7, 2020. . https://doi.org/10.1101/2020.06.07.138867doi: bioRxiv preprint 
indicating that the trans-repression but not induction is occurring. The transcription of Id2 seems 
not to be affected by any of the treatments used in this study and therefore it can be concluded 
that Id2 is not regulated by PPARβ/δ in pulmonary artery.  
By combining these findings with the inflammatory response, it can be deduced that in 
pulmonary artery GW0742 triggers both induction and trans-repression, resulting in a pro-
inflammatory state of PPARβ/δ. Interestingly, the presence of GW0742 and GSK3787 together 
inhibits the induction mode of action but activates the trans-repression mode of action through 
NF-κB, which is the treatment that produces the strongest anti-inflammatory effect. Taken 
together, it suggests that GW0742 triggers the induction mechanism, which is pro-inflammatory, 
and GW0742 plus GSK3787 switches PPARβ/δ to the trans-repression mechanism through NF-
κB which is responsible for the anti-inflammatory effects of PPARβ/δ in LPS-induced inflamed 
pulmonary artery. 
In bronchi, Angptl-4 is not expressed but Pdk-4 is significantly increased by GW0742. On the 
contrary, in lung parenchyma Angptl-4 is significantly increased by GW0742 but Pdk-4 is not 
affected by PPARβ/δ ligands. This result suggests that the induction mechanism of action of 
PPARβ/δ is occurring in bronchi and lung parenchyma. On the other side, the transcription of 
Timp-1, Serpine-1 and Id2 does not vary with the treatments, indicating that trans-repression 
mode is not a major mechanism of action of PPARβ/δ in these tissues, which can explain the 
weaker inhibition of the inflammatory response.  
It has been shown in several studies that Nos2 is regulated by PPARβ/δ (35,45,46), although it 
has not been described whether this regulation is via induction or trans-repression. In our hands, 
LPS increases Nos2 expression in all tissues tested, however the regulation of its expression 
by PPARβ/δ is different depending on the tissue. In pulmonary artery, GW0742 represses the 
expression of Nos2, suggesting that PPARβ/δ is inhibiting Nos2 through the induction mode of 
action. Surprisingly, in bronchi GW0742 significantly increases the transcription of Nos2 
compared to LPS, suggesting that PPARβ/δ enhances the expression of Nos2 through the 
.CC-BY-NC-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted June 7, 2020. . https://doi.org/10.1101/2020.06.07.138867doi: bioRxiv preprint 
induction mode of action, and in parenchyma the expression of Nos2 is not regulated by 
PPARβ/δ. This result indicates that the cell/tissue type is another important co-determinant of 
the type of response of the PPARβ/δ target genes - different co-regulators might be available 
depending on the tissue, resulting in alteration of the dynamics of transcriptional complexes and 
interactions with DNA binding sites. Thus, there are multiple levels of regulation by which 
PPARβ/δ can influence the expression of target genes. 
Further to this, It has been suggested that the large ligand binding pocket of PPARβ/δ can 
accommodate more than one ligand, resulting in an unusual PPAR:ligand stoichiometries that 
could trigger inactive receptor conformations (28), a possibility that was further investigated 
using in silico methods. 
Firstly, the two PPARβ/δ agonists (GW0742 and L-165042) and two antagonists (GSK3787 and 
GSK0660) were docked into the PPARβ/δ binding site. It was found that the agonists and 
antagonists have a different binding profile within the binding pocket: the same three amino 
acids His287, His413 and Tyr437 form polar interactions with the two agonists tested - but they 
do not bind the antagonists - and the amino acids Thr252 and Asn307 are more prone to bind 
the antagonists.  
This finding agrees with previous results were GW0742 was docked to another PPARβ/δ crystal 
structure (PDB: 3GZ9) using another docking software (Glide), and the same three amino acids 
bound to GW0742 (47). Furthermore, several studies co-crystallized PPARβ/δ with different 
agonists both synthetic, such as iloprost (48), the fibrate GW2433 (49), or GW501516 (50) and 
natural PPARβ/δ agonists such as with eicosapentaenoic acid (EPA) (49), and in all cases the 
agonists showed polar bindings with the same three amino acids His287, His413 and Tyr437.  
It is worth mentioning another study where the authors selected 5 compounds that potentially 
bound PPARβ/δ and performed a luciferase transactivation assay to biologically test if these 
compounds activate PPARβ/δ. They further analyzed two of them by docking and molecular 
dynamics (MD) simulation, one compound that activated PPARβ/δ (Compound 1) and another 
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one that did not activate PPARβ/δ (Compound 2). The docking and MD simulation results for 
the Compound 1 showed an interaction with His287, His413 and Tyr437, and the results for 
Compound 2 showed an interaction with Thr252 (51). 
This suggests the possibility that the different binding profile between agonists and antagonists 
can provoke a different 3D conformational change that might explain why PPARβ/δ binds to co-
repressors instead of co-activators and vice versa. Taking all this into account it can be 
hypothesized that a ligand that shows a high binding affinity and is predicted to form polar bonds 
with His287, His413 and Tyr437 will most likely behave as agonist. On the contrary, if one ligand 
shows high binding affinity but it is predicted to bind other residues such as Thr252 and Asn307 
it is more likely that it will behave as antagonist.  
Next, the possibility of two ligands binding into the PPARβ/δ binding pocket at same time was 
investigated. The treatment of tissues with only GW0742 allows two possibilities: the binding of 
one or two molecules into LBD. If a second molecule of GW0742 binds to PPARβ/δ, this 
molecule is predicted to bind not too far from the most stable binding site and with the same 
binding affinity and residue interaction (Arg258) than the 8th best pose predicted for the first 
molecule. Similarly, when only GSK3787 is present in the treatment, a second molecule of 
GSK3787 is predicted to bind also not far away from its most stable binding site and with 
favorable binding affinity, and what is more, it will still form polar bonds with Thr252, an amino 
acid that is predicted to bind GSK3787 in five out of eight most stable poses predicted by 
docking, including the first three.  
For the treatment of tissues with GW0742+GSK3787 all the options mentioned above still apply 
but two more options are available: GW0742 binds first and GSK3787 after or GSK3787 binds 
first and GW0742 after. When GW0742 binds first, GSK3787 can still bind very close to its most 
stable binding site with a very favorable binding affinity, and what is more, still binds the residue 
Thr252. If GSK3787 binds first, GW0742 is predicted to bind very far away from the most stable 
binding site, at the entrance of the binding pocket, and as a consequence it will have a very 
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different binding profile forming polar bonds with Trp228 and Lys229, two residues that did not 
show any interaction with ligands before. Similar analysis can be done with the other pair of 
agonist and antagonist L-165041 and GSK0660. 
Taking into account the docking scores and molecular poses of the ligands, all possibilities 
described above have very favorable energies for it to happen. That opens a whole new scenario 
of possibilities that could dramatically change the 3D conformation of PPARβ/δ in ways that 
have not been thought of before, resulting in the binding of different co-regulators, which 
ultimately could change the PPARβ/δ response from induction to trans-repression or vice versa.  
To our knowledge, this is the first time that the possibility of binding two ligands simultaneously 
into the PPARβ/δ binding pocket has been explored. The results suggest that this possibility is 
very likely to happen with very favorable affinity energies, and it is worth considering when 
designing and interpreting experiments where PPARβ/δ is ligand-activated. 
In summary, this is a multidisciplinary approach of the study of PPARβ/δ that provides novel 
information about its functioning at molecular level. In the model used here the presence of 
agonist and antagonist at same time switches the PPARβ/δ mode of action from induction to 
trans-repression, and the trans-repression mode of action was linked with anti-inflammatory 
effects. Among the tissues tested, PPARβ/δ seems to play a more important role in the regulation 
of inflammation in the pulmonary artery.  A characteristic PPARβ/δ-ligand binding profile which is 
different for agonists and antagonists is also described. PPARβ/δ agonists form polar bonds with 
His287, His413 and Tyr437, while antagonists are more promiscuous about which amino acids 
they bind to, although they are very prone to bind Thr252 and Asn307. The possibility of two 
agonists binding at same time into the PPARβ/δ binding pocket was also explored, and all the 
options studied seem feasible with favorable binding energies, suggesting the need for caution 
when designing and interpreting the results of experiments using PPARβ/δ ligands. 
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Experimental procedures 
Reagents 
The PPARβ/δ ligands GW0742, GSK3787, L-165042 and GSK0660 as well as 1400W, LPS 
O55:B5, sulfanilamide and naphthylethylenediamine dihydrochloride were purchased from 
Sigma. Sodium nitrate, orthophosphoric acid and DMSO were purchased from Fisher Scientific. 
Primers from Applied Biosystem: β-actin (Rn00667869_m1), Pdk-4 (Rn00585577_m1), Angptl-
4 (Rn015228817_m1), Nos2 (Rn00561646_m1), Serpine-1 (Rn01481341_m1), Timp-1 
(Rn01430873_m1), Id2 (Rn01495280_m1). 
Animals 
Male Wistar rats (350-450 g) were sourced from Charles River (UK) and housed in pairs in 
standard cages (Tecniplast 2000P) with sawdust (Datesand grade 7 substrate) and shredded 
paper wool bedding with water and food (5LF2 10% protein LabDiet) in the Biological Services 
Unit at the University of Hertfordshire. The housing environment was maintained at a constant 
temperature of 22 ± 2 oC, under a 12 h light/dark cycle (lights on: 07:00 to 19:00 h). All testing 
was conducted under the light phase of the animals’ light/dark cycle, and care was taken to 
randomize treatment sequences to control for possible order effects.  
All experiments were approved by the local ethics committee, and conducted in accordance with 
the guidelines established by the Animals (Scientific Procedures) Act, 1986 and European 
directive 2010/63/EU. Rats were euthanized according to schedule 1 procedure by CO2 
asphyxiation followed by cervical dislocation. Lungs were removed and immediately placed in 
physiological saline solution (PSS) buffer (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.17 mM 
MgSO4, 1 mM KH2PO4, 5.5 mM, glucose, 25 mM NaHCO3 and 0.03 mM Na2EDTA). 
Following dissection, tissues were incubated in 1% v/v penicillin/streptomycin in DMEM under 
5% v/v CO2 at 37 oC in the required treatment (detailed in Table 1) for up to 24 hours. After 
incubation, the culture medium was removed and stored at -20 oC until Greiss assay or IL-6 
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ELISA analysis. The tissues were stored at -80 oC until needed for mRNA extraction for qRT-
PCR. 
Quantification of PPARβ/δ expression in lung tissues by enzyme-linked immunosorbent 
assay (ELISA) 
The expression of PPARβ/δ on pulmonary artery, bronchi and parenchyma from naïve rats was 
measured using Rat PPARβ/δ ELISA kit (Abbkine) according to the manufacturer’s instructions. 
Briefly, the dissected tissues were homogenized with liquid N2 using a mortar and a pestle, and 
the proteins were extracted in ice-cold phosphate buffered saline (PBS) with proteinase inhibitor 
cocktail in a ratio 9 mL PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7.4) per g tissue. The samples were then sonicated 3x30 seconds and centrifuged for 5 min at 
5000 g. The supernatant was collected, and the protein concentration was quantified by BCA 
assay. Then, 50 µL of standards and samples were added in duplicate to the plate containing 
pre-coated anti-PPARβ/δ and incubated 45 min at 37 oC. The wells were washed and incubated 
with 50 µL of the horseradish peroxidase (HRP)-conjugated detection antibody for another 30 
min at 37 oC. The wells were washed again and incubated in the dark with the chromogen 
solution for 15 min at 37 oC. Finally, the reaction was stopped by adding 50 µL of Stop solution 
and the plate was immediately measured in a microplate reader. The concentrations of PPARβ/δ 
were determined by comparison of OD450 to a standard curve (0-8 ng/mL). 
Quantification of nitric oxide released by lung tissues by the Griess assay 
An aliquot of the culture medium (50 µL) thawed on ice was mixed with an equal volume of 
Griess reagent (mixture of equal volumes Griess reagent 1 and Griess reagent 2 containing 
sulfanilamide 1% w/v + orthophosphoric acid 5% v/v and naphthylethylenediamine 
dihydrochloride 0.5% w/v respectively). The concentration was determined by comparison of the 
OD540 to a standard curve of solutions of sodium nitrite (0-1 mM). 
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Quantification of IL-6 released by lung tissues by ELISA 
The release of IL-6 by lung tissues to the culture medium was measured using Rat IL-6 DuoSet 
ELISA kit (R&D Systems) according to the manufacturer’s instructions. Briefly, all samples and 
standards were conducted in duplicate to a microtiter plate containing the capture antibody. After 
two hours of incubation the wells were washed and incubated with the detection antibody for 
another two hours. The wells were washed again and incubated in the dark with Streptavidin-
HRP for 20 min. The wells were washed once more and incubated in the dark with Substrate 
Solution. After 20 min the stop solution was added and immediately measured in a microplate 
reader. The readings at 540 nm were subtracted from the readings at 450 nm and the 
concentrations of samples were determined by comparison with the standard curve (0-8 ng/mL). 
Quantitative real time-polymerase chain reaction (qRT-PCR) 
Total RNA was extracted from tissues using RNeasy Fibrous Tissue Mini Kit (Quiagen). The 
tissues were first pulverized in a pestle with liquid N2 and the RNA was then extracted following 
the manufacturer’s instruction and stored at -80 oC until use. The quality and concentration of 
the RNA was measured using Nanodrop (SimpliNano, GE Healthcare Life Science) at a 
wavelength of 260 nm. Further to that, the degradation of RNA was checked in a 1% w/v agarose 
gel, and the DNA contamination of the RNA was checked by PCR. To do that, genomic DNA 
was also extracted from the tissues using PureLink Genomic DNA mini kit from Invitrogen 
following the manufacturer’s instructions and used as a positive control of the PCR, and two 
primers for the housekeeping gene β-actin were designed (forward 
CTGGTCGTACCACTGGCATT, reverse AATGCCTGGGTACATGGTGG). The termociclator 
Mastercycler Nexus gradient (Eppendorf) was set with the following PCR protocol: 95 °C for 10 
min, 40 cycles of 95 °C for 30 s, 56 °C for 30 s and 72 °C for 30 s, 72 °C for 10 min and hold at 
4°C. 
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cDNA was obtained by reverse transcription (RT) using iScript cDNA synthesis kit (Bio-Rad) 
following the manufacturer’s instructions. The RT was performed using a thermociclator 
Stratagene Mx3005P (Agilent Technologies) with the following steps: 5 min at 25 oC, 20 min at 
46 oC, 5 min at 95 oC, and hold at 4 oC. 
qRT-PCR was performed to analyze mRNA expression using a Taqman System. Briefly, 10 µL 
of reaction mix containing the primers and cDNA was incubated in a 96 well-plate following the 
cycle conditions: 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 1 min.  
Docking 
The ability of drugs to bind into protein active sites was investigated using AutoDock/Vina with 
Pymol and Ligplot+ as a graphical user interface. For the docking simulations, the PPARβ/δ 
crystal structure 3TKM was selected for having one of the highest resolutions (1.95 Å). The PDB 
file was downloaded from Protein Data Bank. Water molecules, ligands and other hetero atoms 
were removed from the protein structure, and the addition of hydrogen atoms to the protein was 
performed using AutoDock Tools version 1.5.6. The grid was set manually to cover the active 
site. The file was saved as a pdbqt file. 
The ligand molecule structures were drawn in ChemSketch, the energy was minimized and 
saved in PDB format, and converted into a pdbqt file with AutoDock Tools version 1.5.6. 
Molecular docking was performed with the software AutoDock Vina and all parameters set as 
default. Results with minor calculated free energy variations were analyzed using Pymol version 
1.7.4 and LigPlot+ version1.4.5 softwares. 
For the docking of two molecules, the 3TKM PDB file without hetero atoms was combined with 
the best docking result of each ligand in one single PDB file, one PDB file per ligand. These files 
were opened in Autodock Tools, H2 were added, the grid was set manually and saved in a new 
pdbqt file. This file was used for the docking with the second molecule. 
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Statistical analysis 
Statistical comparisons were performed on GraphPad Prism 5.0 software using one-way or two-
way ANOVA with Bonferroni’s post hoc analysis for NO and IL-6 detection assays, and Dunnett’s 
post hoc analysis for qRT-PCR. The values are expressed as observed mean ± SEM. Data was 
normalized previously to the statistical analysis. In short, data from NO and IL-6 detection assays 
was normalized against the group treatment LPS and expressed as a fold change. The relative 
quantification of genes analyzed by qRT-PCR was calculated with the comparative CtΔΔ 
method, β-actin was used as endogenous control and data was normalized against the control 
group. 
Values of p<0.05 were considered statistically significant. When the level of probability (P) is 
less than 0.05 (*), less than 0.01 (**) or less than 0.001 (***), the effect of the difference was 
regarded as significance. 
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Figure 1. NO production by lung tissues over the time. A) Pulmonary artery (n=13), B) bronchi (n=9) and 
parenchyma (n=14) were dissected, cut into six pieces and incubated under six different treatments of 
different combinations of 1 µg/mL LPS, 100 nM GW0742, 1 µM GSK3787, 10 µM 1400W; the NO production 
was measured at 8 h, 20 h and 24 h of incubation. Significant difference between treatments was analyzed 
by two-way ANOVA followed by Bonferroni post-hoc test and the data are presented as mean ± standard 
error of the mean. *=P<0.05, **=P<0.01, ***=P<0.001 compared with vehicle; f=P<0.05, ff=P<0.01, 
fff=P<0.001 compared with LPS; #=P<0.05 compared with LPS+GW0742. 
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 Figure 2. NO and IL-6 production by pulmonary artery. Rat pulmonary artery rings were treated with two 
combinations of PPARβ/δ agonist-antagonist and iNOS inhibitor 1400W: A-C) 100 nM GW0742 – 1 µM 
GSK3787 – 100 µM 1400W B-D) 1 µM L-165041 – 1 µM GSK0660 – 100 µM 1400W. NO and IL-6 
production was measured after 24 h and normalized with LPS: A) The average of NO production in LPS was 
used for the normalization of the data and the number of samples per treatment is written at the top of the 
bar; B) each experiment was normalized with its own LPS treatment (n=9). C) The average of IL-6 production 
with LPS treatment was used for the normalization of the data and the number of samples per treatment is 
written at the top of the bar; D) each experiment was normalized with its own LPS treatment (n=9). Significant 
difference between treatments was analyzed by one-way ANOVA followed by Bonferroni post-hoc test and 
the data are presented as mean ± standard error of the mean. ***=P<0.001 compared with vehicle; ff=P<0.01, 
fff=P<0.001 compared with LPS; #=P<0.05, ###=P<0.001 compared with LPS+GW0742. 
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 Figure 3. Expression of genes regulated by PPARβ/δ in the pulmonary artery. The expression of different 
PPARβ/δ target genes was measured after 24 h incubation under five different treatments: vehicle (0.01% 
DMSO); 1 µg/mL LPS; 1 µg/mL LPS + 100 nM GW0742; 1 µg/mL LPS + 1 µM GSK3787; and 1 µg/mL LPS 
+ 100 nM GW0742 + 1 µM GSK3787 (n=4-5). Relative quantitation was calculated with the comparative 
CtΔΔ method and normalized against β-actin as an endogenous control. Significant difference between 
treatments was analyzed by one-way ANOVA followed by Dunnett’s post-hoc test and the data are presented 
as mean ± standard error of the mean. ***=P<0.001, **=P<0.01 and *=P<0.05 compared with LPS. 
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Table 2. Best eight docking hits of four ligands into PPARβ/δ (PBD: 3TKM). In green are the residues 
more likely to bind agonists and in red the residues more likely to bind antagonists 
 
The best orientation of each ligand was selected for further analysis using Pymol and Ligplot+. 
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 Figure 4. Analysis of GW0742 docked into PPARβ/δ (PBD:3TKM). A) Representation of the most stable 
GW0742 docking conformation (green) compared to the GW0742 of the crystal structure (pink). B) 3D detail 
of the amino acids forming polar bindings with GW0742 calculated by Pymol. C) Schematic 2D representation 
of the interaction between PPARβ/δ LBD and GW0742 calculated using Ligplot+. The green dashed lines 
indicate polar interactions and the red spoked arcs indicate hydrophobic interactions. Color coding of atoms: 
red O, blue N, mustard S, pink C of GW0742 from the crystal structure, green C of GW0742 docked into the 
crystal structure, cyan C from PPARβ/δ. 
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 Figure 5. Analysis of GSK3787 docked into PPARβ/δ (PBD:3TKM). A) Representation of the most stable 
GSK3787 docking conformation (yellow) compared to the GW0742 of the crystal structure (pink). B) 3D detail 
of the amino acids forming polar bindings with GSK3787 calculated by Pymol. C) Schematic 2D 
representation of the interaction between PPARβ/δ LBD and GSK3787 calculated using Ligplot+. The green 
dashed lines indicate polar interactions and the red spoked arcs indicate hydrophobic interactions. Color 
coding of atoms: red O, blue N, mustard S, pink C of GW0742 from the crystal structure, yellow C of GSK3787 
docked into the crystal structure, cyan C from PPARβ/δ. 
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Table 3. Docking prediction of binding affinities and amino acids forming polar interactions with the 
PPARβ/δ ligands bound into the LBD. The affinity of the binding was predicted by Autodock Vina and the 
best hit was analyzed on Pymol. 
Ligand 1 Ligand 2 
  
Molecule 
Affinity 
(Kcal/mol) 
Aa with polar 
interactions 
  
Molecule 
Affinity 
(Kcal/mol) 
Aa with polar 
interactions 
  
GW0742 
  
-11.1 
His287 
His413 
Tyr437 
GW0742 -8.5 Arg258 
GSK3787 -7.7 Trp228 
Thr252 
  
GSK3787 
  
-9.1 
  
Thr252 
Asn307 
GW0742 -8.1 Trp228 
Lys229 
GSK3787 -7.4 Thr253 
His413 
  
  
  
L-165041 
  
  
  
-8.7 
  
  
His287 
His413 
Tyr437 
  
  
L-165041 
  
  
-8.3 
Met192 
Cys251 
Thr252 
Thr256 
Ile290 
Ala306 
GSK0660 -6.5 Arg198 
Asn339 
  
GSK0660 
  
-8.6 
Arg248 
Thr252 
Ala306 
Asn307 
L-165041 -8.1 Thr253 
His413 
GSK0660 -8.9 Thr252 
Thr253 
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 Figure 6. Analysis of GW0742 and GSK3787 docked into PPARβ/δ+GW0742. A second molecule of 
GW0742 (A, B) or GSK3787 (C, D) was docked into the LBD of PPARβ/δ containing one molecule of 
GW0742. A) Representation of how two GW0742 molecules bind into the PPARβ/δ binding pocket at same 
time. B) Detail of the amino acids interacting with the second molecule of GW0742. C) Representation of 
how one molecule of GW0742 first and then one molecule of GSK3787 bind into the PPARβ/δ binding pocket 
at same time. D) Detail of the amino acids interacting with the second molecule of GSK3787. Color coding 
of atoms: red O, blue N, mustard S, cyan C PPARβ/δ and GW0742 that binds first within the binding pocket, 
green C of GW0742 that binds second into the binding pocket, yellow C of GSK3787 that binds second into 
the binding pocket. 
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 Figure 7. Analysis of GW0742 and GSK3787 docked into PPARβ/δ+GSK3787. A second molecule of 
GW0742 (A, B) or GSK3787 (C, D) was docked into the LBD of PPARβ/δ containing one molecule of 
GSK3787. A) Representation of how one molecule of GSK3787 first and then one molecule of GW0742 bind 
into the PPARβ/δ binding pocket at same time. B) Detail of the amino acids interacting with the second 
molecule of GW0742. C) Representation of how two molecules of GSK3787 bind into the PPARβ/δ binding 
pocket at same time. D) Detail of the amino acids interacting with the second molecule of GSK3787. Color 
coding of atoms: red O, blue N, mustard S, grey C PPARβ/δ and GSK3787 that binds first within the binding 
pocket, green C of GW0742 that binds second into the binding pocket, yellow C of GSK3787 that binds 
second into the binding pocket.  
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